Pharsight

Lupron Depot is owned by Abbvie Endocrine Inc.

Lupron Depot contains Leuprolide Acetate.

Lupron Depot has a total of 2 drug patents out of which 1 drug patent has expired.

Expired drug patents of Lupron Depot are:

Lupron Depot was authorised for market use on 22 December, 1995.

Lupron Depot is available in injectable;injection dosage forms.

Lupron Depot can be used as palliative treatment of prostate cancer.

The generics of Lupron Depot are possible to be released after 05 February, 2031.

Application	Filing Date	Opposition Party	Legal Status
EP07859925A	2020-12-16	Instone Terry/ Read Howard Graham/Appleyard Lees IP LLP	Granted and Under Opposition
EP02738838A	2007-02-16	QLT USA, Inc.	Patent maintained as amended
EP02738838A	2006-05-18	MediGene Aktiengesellschaft	Patent maintained as amended
EP02738838A	2006-05-18	Astellas B.V. et al.	Patent maintained as amended

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8815801	ABBVIE ENDOCRINE INC	Controlled release composition and method of producing the same	Jun, 2022 (8 months ago)
US8921326	ABBVIE ENDOCRINE INC	Sustained-release composition and method for producing the same	Feb, 2031 (7 years from now)